|
Addictive drug
|
Manipulation
|
Target
|
Subjects
|
Main findings/ References
|
| Opioids |
Suvorexant |
Dual OX1/2R |
M (mice) |
Decreased morphine tolerance and dependence / decreased increased levels of CREB and p-ERK proteins98
|
|
|
SB-334867 |
OX1R |
M |
Administration of SB-334867 prevented morphine-induced sensitivity to locomotor activity in mice100
|
|
|
SB-334867 |
OX1R |
R (rat) |
Significantly reduced naloxone-induced withdrawal syndrome physical symptoms in morphine-dependent rats92
|
|
|
SB-334867 |
OX1R |
R |
Microinjection of SB-334867 into LC dramatically suppresses glutamate-induced morphine withdrawal101
|
|
|
SB-334867 |
OX1R |
M |
Attenuated the symptoms of naloxone-induced withdrawal91
|
|
|
SB-334867 |
OX1R |
R |
Attenuation of morphine-induced CPP (acquisition and expression/micro-injection into VTA)89
|
|
|
SB-334867 |
OX1R |
R |
Intra-DG (dentate gyrus) administration dose-dependently reduced morphine priming-induced reinstatement102
|
|
|
SB-334867 |
OX1R |
R |
Decreased motivation and the cue-induced reinstatement of remifentanil-seeking103
|
|
|
SB-334867 |
OX1R |
R |
Inhibition of increased activity of LC neurons following naloxone administration in morphine-dependent rats93
|
|
|
SB-334867 |
OX1R |
R |
Prevention of naloxone-induced neuronal activation within the LC in morphine-dependent rats/ Decreased cAMP concentration in LC neurons94
|
|
|
SB-334867 |
OX1R |
R |
Significant reduction of physical symptoms of morphine withdrawal syndrome induced by naloxone95
|
|
|
TCS-OX2-29 |
OX2R |
R |
Intra-DG (dentate gyrus) administration dose-dependently reduced morphine priming-induced reinstatement102
|
|
|
TCS-OX2-29 |
OX2R |
R |
Attenuation of morphine-induced CPP (acquisition and expression/micro-injection into VTA)89
|
|
|
NBI-80713 |
OX2R |
R |
Dose-dependently reduced heroin self-administration (systemic administration) 97
|
